CorFlow Therapeutics is developing a technology to identify and treat microvascular obstruction (MVO) in heart attack patients. MVO is common in acute heart attack patients and comes along with a poor prognosis.
Innosuisse – the Swiss Innovation Agency – previously supported the technology’s non-clinical development. Now, it is granting 1.7 million francs over two years to the project, according to a statement. The new grant will support clinical trials, with the first trial on human participants soon to start in Switzerland. For the trials, CorFlow is working with researchers from Swiss universities including the University of Zurich and the Federal Institute of Technology in Zurich (ETH).
CorFlow is also helping finance the clinical trial. It has raised 9.4 million francs from private investors in a seed funding round. In 2019, it plans to run a series A financing round to finance further development and clinical and regulatory activities.
More News
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space